Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

AtriCure, Inc.

NASDAQ: ATRC · Industrial Applications and Services · 5 alerts · CIK 1323885

Share price
$55.31Close, Nov 16
Market cap
$2.82B
Shares outstanding
50.92MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All AtriCure, Inc. filings on SEC EDGAR ↗

4:03 PM ET Form 4
Insider Selling

AtriCure Insider B. Kristine Johnson Sells $143K of Stock

B. Kristine Johnson sold 2,452 shares of AtriCure, Inc. at $58.48 a share, worth $143K in total on Nov 6, 2026. Shares held after the trade: 53,502 (-4.4%).

Value
$143K
Shares
2,452
Price
$58.48
Holding change
-4.4%
Trade date
Nov 6, 2026
4:18 PM ET Form 4
Insider Selling

AtriCure Chief Technical Officer Salvatore Privitera Sells $546K of Stock

Salvatore Privitera, Chief Technical Officer, sold 8,404 shares of AtriCure, Inc. at $65.00 a share, worth $546K in total on Nov 4, 2026. Shares held after the trade: 134,341 (-5.9%).

Value
$546K
Shares
8,404
Price
$65.00
Role
Chief Technical Officer
Holding change
-5.9%
Trade date
Nov 4, 2026
2:03 PM ET 10-Q
Financial Results

AtriCure Q3 2026 Results: Turns Profitable, Net Income $4.06M

AtriCure, Inc. reported a significant turnaround for the nine months ended September 30, 2026, achieving a net income of $13.1 million compared to a net loss of $13.2 million in the prior year period. Revenue grew 14% year-over-year to $449.3 million, driven by strong performance in surgical treatments for atrial fibrillation and left atrial appendage management.

Key figure
Net income $4.06M
4:01 PM ET 8-K
Financial Results

AtriCure Financial Results

AtriCure reported third quarter 2026 worldwide revenue of $154.5 million, a 15% year-over-year increase driven by strong U.S. sales in post-operative pain management and appendage management. The company achieved profitability expansion with net income of $4.1 million and adjusted EBITDA of $26.8 million, while raising its full-year 2026 revenue guidance to a range of $606 million to $610 million.

Term
Q3 2026

“Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution. Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead.”

Michael Carrel, President and Chief Executive Officer
5:01 PM ET Form 4
Insider Selling

AtriCure Chief Technical Officer Salvatore Privitera Sells $271K of Stock

Salvatore Privitera, Chief Technical Officer, sold 4,519 shares of AtriCure, Inc. at $60.00 a share, worth $271K in total on Sep 23, 2026. Shares held after the trade: 142,745 (-3.1%).

Value
$271K
Shares
4,519
Price
$60.00
Role
Chief Technical Officer
Holding change
-3.1%
Trade date
Sep 23, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.